PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW144606View Pathway |
drug action
Brimonidine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:00 Last Updated: October 07, 2023 at 14:00 |
PW146338View Pathway |
drug action
Brilliant green cation Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:58 Last Updated: October 07, 2023 at 17:58 |
PW146931View Pathway |
drug action
Brilliant blue G Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 19:23 Last Updated: October 07, 2023 at 19:23 |
PW132401View Pathway |
Brilliant blue G Drug MetabolismHomo sapiens
Brilliant blue G is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Brilliant blue G passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 21:29 Last Updated: September 21, 2023 at 21:29 |
PW146508View Pathway |
drug action
Brigatinib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:22 Last Updated: October 07, 2023 at 18:22 |
PW128303View Pathway |
drug action
Brexpiprazole Serotonin Action Action PathwayHomo sapiens
Although the exact mechanism of action of brexpiprazole in psychiatric disorders has not been fully elucidated, the efficacy of brexpiprazole may be attributed to combined partial agonist activity at 5-HT1A and dopamine D2 receptors, and antagonist activity at 5-HT2A receptors. Brexpiprazole is predominantly, a 5-HT1A, D2, and D3 partial agonist and a 5-HT2A, 5-HT2B, 5-HT7, alpha1A, alpha1B, alpha1D, and alpha2C antagonist with a chemical formula of 7-{4-[4-(1-Benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one. Brexpiprazole is indicated as adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults. It is also indicated for the treatment of schizophrenia in patients 13 years of age and older. Brexpiprazole is also indicated for the treatment of agitation associated with dementia due to Alzheimer’s disease.
|
Creator: Omolola Created On: August 16, 2023 at 15:41 Last Updated: August 16, 2023 at 15:41 |
PW176324View Pathway |
Brexpiprazole Predicted Metabolism PathwayHomo sapiens
Metabolites of sildenafil are predicted with biotransformer.
|
Creator: Omolola Created On: December 07, 2023 at 15:05 Last Updated: December 07, 2023 at 15:05 |
PW145997View Pathway |
drug action
Brexpiprazole Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:09 Last Updated: October 07, 2023 at 17:09 |
PW128302View Pathway |
drug action
Brexpiprazole Dopamine Agonist Action PathwayHomo sapiens
Although the exact mechanism of action of brexpiprazole in psychiatric disorders has not been fully elucidated, the efficacy of brexpiprazole may be attributed to combined partial agonist activity at 5-HT1A and dopamine D2 receptors, and antagonist activity at 5-HT2A receptors. Brexpiprazole is predominantly, a 5-HT1A, D2, and D3 partial agonist and a 5-HT2A, 5-HT2B, 5-HT7, alpha1A, alpha1B, alpha1D, and alpha2C antagonist with a chemical formula of 7-{4-[4-(1-Benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one. Brexpiprazole is indicated as adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults. It is also indicated for the treatment of schizophrenia in patients 13 years of age and older. Brexpiprazole is also indicated for the treatment of agitation associated with dementia due to Alzheimer’s disease.
|
Creator: Omolola Created On: August 16, 2023 at 15:41 Last Updated: August 16, 2023 at 15:41 |
PW146464View Pathway |
drug action
Brexanolone Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:16 Last Updated: October 07, 2023 at 18:16 |